close
Fox News Flash top headlines are here. Check out what’s clicking on Foxnews.com.
AstraZeneca said on Friday its and Daiichi Sankyo’s cancer drug Enhertu was recommended by the European Medicines Agency’s human medicines committee as a monotherapy to treat patients with a type of non-small cell lung cancer (NSCLC).
The recommendation is based on the mid-stage data where Enhertu showed a confirmed objective response rate of 49% and a median duration of response of 16.8 months in patients previously treated for lung cancer.
EU INITIATES ASSESSMENT OF HUMAN AND LABOR RIGHTS IN BURMA
AstraZeneca’s cancer medicine Enhertu, a drug developed jointly with Japan’s Daiichi Sankyo, is pictured in an undated handout image obtained by Reuters on June 27, 2022. (AstraZeneca/Handout via REUTERS/File photo)
CLICK HERE TO GET THE FOX NEWS APP
The drug is already approved in the European Union as a treatment for patients with an advanced form of breast cancer.
Recommendations made by the human medicines committee will have to be formally approved by the European Commission.
Rep. Keith Self, R-Texas, abruptly adjourned a congressional hearing on Tuesday after Rep. Bill Keating,…
Lawmakers in Oregon are considering three bills that, if passed, would ease public safety requirements…
EXCLUSIVE — The House GOP's campaign committee is taking aim at congressional Democrats for voting…
close Video Search ramps up for missing U.S. student in the Dominican Republic Fox News…
While issues at NASA grew under former President Joe Biden, the space agency prioritized embedding…
FIRST ON FOX: Sen. Roger Marshall, R-Kan., is introducing new legislation to make President Donald…